About Diacylglycerol lipase-alpha
Diacylglycerol lipase-alpha (DAGLA) is a protein
from Homo sapiens identified by UniProt accession
Q9Y4D2, 1042 residues long.
MolForge cross-references it against 0 known binders and
90 disease associations.
Target properties
| Protein name | Diacylglycerol lipase-alpha |
|---|
| UniProt accession | Q9Y4D2 |
|---|
| Gene | DAGLA |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1042 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (90)
Diseases linked to this target (Open Targets).
- benign paroxysmal tonic upgaze of childhood with ataxia · score 0.49
- Ataxia · score 0.46
- spinocerebellar ataxia type 20 · score 0.37
- Intellectual disability · score 0.37
- congenital nystagmus · score 0.37
- wellbeing measurement · score 0.28
- autosomal dominant cerebellar ataxia · score 0.27
- breast adenocarcinoma · score 0.25
- linoleic acid measurement · score 0.23
- alpha-linolenic acid measurement · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9Y4D2-F1 | alphafold | PREDICTED | 63.00 | — |
Amino-acid sequence (1042 residues)
MPGIVVFRRR WSVGSDDLVL PAIFLFLLHT TWFVILSVVL FGLVYNPHEA CSLNLVDHGR GYLGILLSCM IAEMAIIWLS MRGGILYTEP RDSMQYVLYV RLAILVIEFI YAIVGIVWLT QYYTSCNDLT AKNVTLGMVV CNWVVILSVC ITVLCVFDPT GRTFVKLRAT KRRQRNLRTY NLRHRLEEGQ ATSWSRRLKV FLCCTRTKDS QSDAYSEIAY LFAEFFRDLD IVPSDIIAGL VLLRQRQRAK RNAVLDEANN DILAFLSGMP VTRNTKYLDL KNSQEMLRYK EVCYYMLFAL AAYGWPMYLM RKPACGLCQL ARSCSCCLCP ARPRFAPGVT IEEDNCCGCN AIAIRRHFLD ENMTAVDIVY TSCHDAVYET PFYVAVDHDK KKVVISIRGT LSPKDALTDL TGDAERLPVE GHHGTWLGHK GMVLSAEYIK KKLEQEMVLS QAFGRDLGRG TKHYGLIVVG HSLGAGTAAI LSFLLRPQYP TLKCFAYSPP GGLLSEDAME YSKEFVTAVV LGKDLVPRIG LSQLEGFRRQ LLDVLQRSTK PKWRIIVGAT KCIPKSELPE EVEVTTLAST RLWTHPSDLT IALSASTPLY PPGRIIHVVH NHPAEQCCCC EQEEPTYFAI WGDNKAFNEV IISPAMLHEH LPYVVMEGLN KVLENYNKGK TALLSAAKVM VSPTEVDLTP ELIFQQQPLP TGPPMPTGLA LELPTADHRN SSVRSKSQSE MSLEGFSEGR LLSPVVAAAA RQDPVELLLL STQERLAAEL QARRAPLATM ESLSDTESLY SFDSRRSSGF RSIRGSPSLH AVLERDEGHL FYIDPAIPEE NPSLSSRTEL LAADSLSKHS QDTQPLEAAL GSGGVTPERP PSAAANDEEE EVGGGGGGPA SRGELALHNG RLGDSPSPQV LEFAEFIDSL FNLDSKSSSF QDLYCMVVPE SPTSDYAEGP KSPSQQEILL RAQFEPNLVP KPPRLFAGSA DPSSGISLSP SFPLSSSGEL MDLTPTGLSS QECLAADKIR TSTPTGHGAS PAKQDELVIS AR
Explore Diacylglycerol lipase-alpha with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets